Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial - Antonia, Scott J.; Jäger, Dirk (The lancet. Oncology, 2016)
Gesehen am 13.03.2018